BD
BDX.US Becton Dickinson and Company
- Market cap
- USD 59.4B
- P/E
- 42.7x
- P/B
- 2.38x
- ROE
- 4.6%
- Dividend yield
- 1.97%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is BDX.US undervalued?
Graham numberBDX.US trades 112.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Becton Dickinson and Company fundamental analysis
No fundamental analysis for Becton Dickinson and Company yet.
Becton Dickinson and Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, …
Full company profileBecton Dickinson and Company financial statements
Becton Dickinson and Company annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 12.1B | 16.0B | 17.3B | 16.1B | 19.1B | 18.9B | 19.4B | 20.2B | 21.8B | 19.5B |
| Gross Profit | 5.97B | 7.27B | 8.29B | 6.80B | 8.63B | 8.48B | 8.17B | 9.13B | 9.92B | 9.21B |
| Operating Income | 1.52B | 1.51B | 1.76B | 912M | 2.25B | 2.28B | 2.11B | 2.40B | 2.58B | 2.26B |
| EBITDA | 2.59B | 3.86B | 4.07B | 3.06B | 4.39B | 4.41B | 4.40B | 4.82B | 4.96B | 4.61B |
| Net Income | 1.10B | 311M | 1.23B | 874M | 2.09B | 1.78B | 1.48B | 1.71B | 1.68B | 1.15B |
| EPS | 4.92 | 1.18 | 4.49 | 3.09 | 7.16 | 6.19 | 5.15 | 5.86 | 5.84 | 4.09 |
| Balance Sheet | ||||||||||
| Total Assets | 37.7B | 53.9B | 51.8B | 54.0B | 53.9B | 52.9B | 52.8B | 57.3B | 55.3B | 50.8B |
| Total Liabilities | 24.8B | 32.9B | 30.7B | 30.2B | 30.2B | 27.7B | 27.0B | 31.4B | 29.9B | 26.1B |
| Shareholders' Equity | 12.9B | 21.0B | 21.1B | 23.8B | 23.7B | 25.3B | 25.8B | 25.9B | 25.4B | 24.7B |
| Cash & Short-term Investments | 14.2B | 1.16B | 566M | 2.85B | 2.40B | 1.17B | 1.42B | 2.30B | 859M | 733M |
| Total Debt | 18.9B | 21.5B | 19.4B | 17.9B | 18.4B | 17.0B | 16.8B | 21.6B | 19.2B | 16.3B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.55B | 2.87B | 3.33B | 3.54B | 4.65B | 2.63B | 2.99B | 3.80B | 3.43B | 3.37B |
| Capital Expenditure | 727M | 895M | 957M | 810M | 1.23B | 973M | 874M | 725M | 760M | 672M |
| Free Cash Flow | 1.82B | 1.97B | 2.37B | 2.73B | 3.42B | 1.66B | 2.12B | 3.07B | 2.67B | 2.93B |
| Ratios | ||||||||||
| ROE | 8.5% | 1.5% | 5.8% | 3.7% | 8.8% | 7.0% | 5.8% | 6.6% | 6.6% | 4.6% |
| ROA | 2.9% | 0.6% | 2.4% | 1.6% | 3.9% | 3.4% | 2.8% | 3.0% | 3.0% | 2.3% |
| Net Profit Margin | 9.1% | 1.9% | 7.1% | 5.4% | 10.9% | 9.4% | 7.7% | 8.4% | 7.7% | 5.9% |
| Debt to Equity | 1.46x | 1.02x | 0.92x | 0.75x | 0.78x | 0.67x | 0.65x | 0.83x | 0.76x | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Becton Dickinson and Company dividends
- Dividend yield
- 1.97%
- Forward dividend
- 4.24 USD
- Payout ratio
- 101.3%
- Ex-dividend date
- Dec 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 1.16B | 4.15 | 101.3% |
| 2025 | USD 1.20B | 4.17 | 71.3% |
| 2024 | USD 1.10B | 3.78 | 64.5% |
| 2023 | USD 1.11B | 3.86 | 75.1% |
| 2022 | USD 1.08B | 3.77 | 60.8% |
| 2021 | USD 1.05B | 3.59 | 50.1% |
| 2020 | USD 1.03B | 3.63 | 117.4% |
| 2019 | USD 984M | 3.58 | 79.8% |
| 2018 | USD 927M | 3.50 | 298.1% |
| 2017 | USD 677M | 3.03 | 61.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1272:1000 on Feb 10, 2026.
Who owns Becton Dickinson and Company
- Insiders 0.43%
- Institutions 98.74%
- Public & others 0.82%
- Shares outstanding 272M
- Free float 272M
Top funds holding BDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| First Eagle Global A | 9.15M | 3.36% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 8.64M | 3.17% | -1.28% | Sep 2026 |
| Vanguard 500 Index Investor | 7.15M | 2.63% | -2.23% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 5.83M | 2.14% | -2.14% | Sep 2026 |
| iShares Core S&P 500 ETF | 3.63M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 3.54M | 1.30% | -1.03% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 3.31M | 1.22% | -0.25% | Oct 2026 |
| Putnam Large Cap Value A | 3.06M | 1.12% | 0.00% | Sep 2026 |
| Vanguard Equity-Income Inv | 2.62M | 0.96% | -9.65% | Sep 2026 |
| Vanguard MStar Value Index Investor | 2.59M | 0.95% | -1.43% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 1.99M | 0.73% | +0.88% | Oct 2026 |
| State Street® SPDR® S&P® Dividend ETF | 1.80M | 0.66% | 0.00% | Oct 2026 |
| Vanguard MStar Mid Cap Value ETF | 1.70M | 0.62% | -4.67% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 1.54M | 0.57% | -1.20% | Sep 2026 |
| Vanguard Institutional Index I | 1.44M | 0.53% | -2.21% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 1.39M | 0.51% | 0.00% | Sep 2026 |
| Invesco Value Opportunities A | 1.35M | 0.49% | +6.43% | Sep 2026 |
| MFS Mid Cap Value A | 1.33M | 0.49% | -0.80% | Sep 2026 |
| T. Rowe Price Equity Income | 1.27M | 0.47% | 0.00% | Sep 2026 |
| FPA Crescent | 1.24M | 0.46% | 0.00% | Sep 2026 |
Top institutions holding BDX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Arnhold & S. Bleichroeder Advisers, LLC | 27.6M | 10.14% | +131.64% | Jun 2026 |
| BlackRock Inc | 24.6M | 9.03% | -5.97% | Jun 2026 |
| Vanguard Capital Management, LLC | 18.0M | 6.60% | -2.72% | Jun 2026 |
| State Street Corp | 15.0M | 5.51% | +8.52% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 15.0M | 5.50% | -2.24% | Jun 2026 |
| Amvescap Plc. | 8.90M | 3.27% | -12.54% | Jun 2026 |
| Massachusetts Financial Services Company | 8.65M | 3.18% | -4.95% | Jun 2026 |
| Geode Capital Management, LLC | 8.14M | 2.99% | +14.55% | Jun 2026 |
| Franklin Templeton Inc | 7.01M | 2.57% | +30.74% | Jun 2026 |
| Wellington Management Company LLP | 6.36M | 2.33% | -3.89% | Jun 2026 |
| Greenhaven Associates Inc | 5.68M | 2.09% | 0.00% | Jun 2026 |
| NORGES BANK | 4.17M | 1.53% | +10.19% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.91M | 1.43% | -11.57% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 3.72M | 1.37% | -61.56% | Jun 2026 |
| American Century Companies Inc | 3.68M | 1.35% | +7.95% | Jun 2026 |
| Charles Schwab Investment Management Inc | 3.40M | 1.25% | +2.23% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.32M | 1.22% | -17.44% | Jun 2026 |
| ClearBridge Advisors, LLC | 3.23M | 1.19% | -21.91% | Jun 2026 |
| Bank of America Corp | 3.14M | 1.15% | +17.63% | Jun 2026 |
| JPMorgan Chase & Co | 2.84M | 1.04% | -20.58% | Jun 2026 |
Becton Dickinson and Company company profile
- Company name
- Becton Dickinson and Company
- Ticker
- BDX.US
- Exchange
- USA Stocks
- Listed since
- Jan 1, 1987
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 60,000
- Fiscal year end
- September
- Address
- 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
- Phone
- 201 847 6800
- Website
- bd.com
About Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Becton Dickinson and Company management
10- Mr. Thomas E. Polen Jr.President, CEO & Chairman · born 1973
- Mr. Michael C. FeldExecutive VP & Chief Revenue Officer · born 1981
- Mr. Vitor RoqueExecutive VP & CFO · born 1983
- Ms. Elizabeth McCombsExecutive VP & CTO · born 1977
- Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP & Chief Scientific Officer
- Mr. Arthur HuExecutive VP and Chief Information & Digital Officer
- Mr. Shawn C. BevecSenior Vice President of Investor Relations
- Ms. Lanesha T. Minnix J.D.Executive VP & General Counsel · born 1975
- Carla BurigattoSenior VP & Chief Communications Officer
- Ms. Meera GopalakrishnanSenior VP & Global Chief Marketing Officer